FATE OF PRIORITY PHARMACEUTICALS AND THEIR MAIN METABOLITES AND TRANSFORMATION PRODUCTS IN MICROALGAE-BASED WASTEWATER TREATMENT SYSTEMS

Abstract The present study evaluates the removal capacity of two high rate algae ponds (HRAPs) to eliminate 12 pharmaceuticals (PhACs) and 26 of their corresponding main metabolites and transformation products. The efficiency of these ponds, operating with and without primary treatment, was compared in order to study their capacity under the best performance conditions (highest solar irradiance). Concentrations of all the target compounds were determined in both water and biomass samples. Removal rates ranged from moderate (40-60%) to high (>60%) for most of them, with the exception of the psychiatric drugs carbamazepine, the β-blocking agent metoprolol and its metabolite, metoprolol acid. O-desmethylvenlafaxine, despite its very low biodegradability in conventional wastewater treatment plants, was removed to certain extent (13-39%) Biomass concentrations suggested that bioadsorption/bioaccumulation to microalgae biomass was decisive regarding the elimination of some non-biodegradable compounds such as venlafaxine and its main metabolites. HRAP treatment with and without primary treatment did not yield significant differences in terms of PhACs removal efficiency. The implementation of HRAPs as secondary treatment is a viable alternative to CAS in terms of overall wastewater treatment (including organic micropollutants), with generally higher removal performances and implying a green, low-cost and more sustainable technology.